The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus Vector
Open accessAbstract
BACKGROUND: The development of an effective human immunodeficiency virus (HIV) vaccine is a high global priority. Here, we report the safety, tolerability, and immunogenicity of a replication-defective recombinant adenovirus serotype 5 (rAd5) vector HIV-1 candidate vaccine. METHODS: The vaccine is a mixture of 4 rAd5 vectors that express HIV-1 subtype B Gag-Pol fusion protein and envelope (Env) from subtypes A, B, and C. Healthy, uninfected adults were randomized to receive 1 intramuscular injection of placebo (n=6) or vaccine at dose levels of 10(9) (n=10), 10(10) (n=10), or 10(11) (n=10) particle units and were followed for 24 weeks to assess immunogenicity and safety. RESULTS: The vaccine was well tolerated but was associated with more reactogenicity at the highest dose. At week 4, vaccine antigen-specific T cell responses were detected in 28 (93.3%) and 18 (60%) of 30 vaccine recipients for CD4(+) and CD8(+) T cells, respectively, by intracellular cytokine staining assay and in 22 (73%) of 30 vaccine recipients by enzyme-linked immunospot assay. Env-specific antibody responses were detected in 15 (50%) of 30 vaccine recipients by enzyme-linked immunosorbant assay and in 28 (93.3%) of 30 vaccine recipients by immunoprecipitation followed by Western blotting. No neutralizing antibody was detected. CONCLUSIONS: A single injection induced HIV-1 antigen-specific CD4(+) T cell, CD8(+) T cell, and antibody responses in the majority of vaccine recipients. This multiclade rAd5 HIV-1 vaccine is now being evaluated in combination with a multiclade HIV-1 DNA plasmid vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544
Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky, W., Farthing, C., & Ho, D. D. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4650-4655.1994 · Cited by 2,495
Self-citationControl of Viremia in Simian Immunodeficiency Virus Infection by CD8 + Lymphocytes
Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., Racz, P., Tenner-Racz, K., Dalesandro, M., Scallon, B. J., et al. (1999) · Science · doi:10.1126/science.283.5403.857 · Cited by 2,187
Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M., & Oldstone, M. B. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.6103-6110.1994 · Cited by 1,882
Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of Viremia
Rosenberg, E. S., Billingsley, J. M., Caliendo, A. M., Boswell, S. L., Sax, P. E., Kalams, S. A., & Walker, B. D. (1997) · Science · doi:10.1126/science.278.5342.1447 · Cited by 1,835
Jin, X., Bauer, D. E., Tuttleton, S. E., Lewin, S., Gettie, A., Blanchard, J., Irwin, C. E., Safrit, J. T., Mittler, J., Weinberger, L., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.6.991 · Cited by 1,407
Shiver, J. W., Fu, T.-M., Chen, L., Casimiro, D. R., Davies, M.-E., Evans, R. K., Zhang, Z.-Q., Simon, A. J., Trigona, W. L., Dubey, S. A., et al. (2002) · Nature · doi:10.1038/415331a · Cited by 1,176
Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K. M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10108-10125.2005 · Cited by 1,070
Self-citationHIV vaccine design and the neutralizing antibody problem
Burton, D. R., Desrosiers, R. C., Doms, R. W., Koff, W. C., Kwong, P. D., Moore, J. P., Nabel, G. J., Sodroski, J., Wilson, I. A., & Wyatt, R. T. (2004) · Nature Immunology · doi:10.1038/ni0304-233 · Cited by 765
Self-citationDevelopment of a preventive vaccine for Ebola virus infection in primates
Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z.-Y., & Nabel, G. J. (2000) · Nature · doi:10.1038/35046108 · Cited by 663
Self-citationKlein, M. R., van Baalen, C. A., Holwerda, A. M., Kerkhof Garde, S. R., Bende, R. J., Keet, I. P., Eeftinck-Schattenkerk, J. K., Osterhaus, A. D., Schuitemaker, H., & Miedema, F. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.4.1365 · Cited by 638
Pantaleo, G., Demarest, J. F., Soudeyns, H., Graziosi, C., Denis, F., Adelsberger, J. W., Borrow, P., Saag, M. S., Shaw, G. M., Sekalytt, R. P., et al. (1994) · Nature · doi:10.1038/370463a0 · Cited by 604
Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96.
Altman, J. D., Moss, P. A. H., Goulder, P., Barouch, D. H., McHeyzer‐Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (2011) · PubMed · Cited by 572
Musey, L., Hughes, J., Schacker, T., Shea, T., Corey, L., & McElrath, M. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710303371803 · Cited by 518
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
Sullivan, N. J., Geisbert, T. W., Geisbert, J. B., Xu, L., Yang, Z.-Y., Roederer, M., Koup, R. A., Jahrling, P. B., & Nabel, G. J. (2003) · Nature · doi:10.1038/nature01876 · Cited by 462
Self-citationNixon, D. F., Townsend, A. R. M., Elvin, J. G., Rizza, C. R., Gallwey, J., & McMichael, A. J. (1988) · Nature · doi:10.1038/336484a0 · Cited by 431
Casimiro, D. R., Chen, L., Fu, T.-M., Evans, R. K., Caulfield, M. J., Davies, M.-E., Tang, A., Chen, M., Huang, L., Harris, V., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.11.6305-6313.2003 · Cited by 400
Folgori, A., Capone, S., Ruggeri, L., Meola, A., Sporeno, E., Ercole, B. B., Pezzanera, M., Tafi, R., Arcuri, M., Fattori, E., et al. (2006) · Nature Medicine · doi:10.1038/nm1353 · Cited by 322
Shiver, J. W., & Emini, E. A. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104344 · Cited by 280
Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 DNA Candidate Vaccine
Graham, B. S., Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Martin, J. E., McCluskey, M. M., Chakrabarti, B. K., Lamoreaux, L., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/509259 · Cited by 223
Self-citationEfficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes
Yang, O. O., Kalams, S. A., Rosenzweig, M., Trocha, A., Jones, N., Koziel, M., Walker, B. D., & Johnson, R. P. (1996) · Journal of Virology · doi:10.1128/jvi.70.9.5799-5806.1996 · Cited by 219
High-level HIV-1 viremia suppresses viral antigen-specific CD4+T cell proliferation
McNeil, A. C., Shupert, W. L., Iyasere, C. A., Hallahan, C. W., Mican, J., Davey, R. T., & Connors, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251539598 · Cited by 211
Sprangers, M. C., Lakhai, W., Koudstaal, W., Verhoeven, M., Koel, B. F., Vogels, R., Goudsmit, J., Havenga, M. J. E., & Kostense, S. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.11.5046-5052.2003 · Cited by 188
Brough, D. E., Lizonova, A., Hsu, C., Kulesa, V. A., & Kovesdi, I. (1996) · Journal of Virology · doi:10.1128/jvi.70.9.6497-6501.1996 · Cited by 172
Adenovirus Vector-Based Vaccines for Human Immunodeficiency Virus Type 1
Barouch, D. H., & Nabel, G. J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.149 · Cited by 168
Self-citationBarouch, D. H., Kunstman, J., Glowczwskie, J., Kunstman, K. J., Egan, M. A., Peyerl, F. W., Santra, S., Kuroda, M. J., Schmitz, J. E., Beaudry, K., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.13.7367-7375.2003 · Cited by 164
HIV-1 Induces Cytotoxic T Lymphocytes in the Cervix of Infected Women
Musey, L., Hu, Y., Eckert, L., Christensen, M., Karchmer, T., & McElrath, M. J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.2.293 · Cited by 160
Moss, P. A. H., Rowland‐Jones, S., Frodsham, P., McAdam, S., Giangrande, P. L. F., McMichael, A. J., & Bell, J. I. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.13.5773 · Cited by 157
Chakrabarti, B. K., Kong, W., Wu, B.-Y., Yang, Z., Friborg, J., Xu, L., King, S. R., Montefiori, D. C., & Nabel, G. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.11.5357-5368.2002 · Cited by 142
Self-citationHarvey, B., Maroni, J. M., O'Donoghue, K. A., Chu, K. W., Muscat, J. C., Pippo, A. L., Wright, C. E., Hollmann, C., Wisnivesky, J. P., Kessler, P., et al. (2002) · Human Gene Therapy · doi:10.1089/10430340152712638 · Cited by 132
Huang, Y., Kong, W., & Nabel, G. J. (2001) · Journal of Virology · doi:10.1128/jvi.75.10.4947-4951.2001 · Cited by 110
Self-citationMascola, J. R., Sambor, A., Beaudry, K. R., Santra, S., Welcher, B. C., Louder, M. K., VanCott, T. C., Huang, Y., Chakrabarti, B. K., Kong, W., et al. (2004) · Journal of Virology · doi:10.1128/jvi.79.2.771-779.2005 · Cited by 108
Self-citationCasimiro, D. R., Tang, A., Chen, L., Fu, T., Evans, R. K., Davies, M.-E., Freed, D. C., Hurni, W. M., Aste-Amézaga, J. M., Guan, L., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.13.7663-7668.2003 · Cited by 85
Rasmussen, H. S., Rasmussen, C. S., Lempicki, M., Durham, R. G., Brough, D. E., King, C. R., & Weichselbaum, R. R. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700518 · Cited by 80
Self-citationStatistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials
Moodie, Z., Huang, Y., Gu, L., Hural, J., & Self, S. G. (2006) · Journal of Immunological Methods · doi:10.1016/j.jim.2006.07.015 · Cited by 68
Self-citationGene delivery of vaccines for infectious disease.
Kr, C., & Pr, J. (2001) · PubMed · Cited by 29
Comprehensive characterization of the 293-ORF6 cell line.
Butman, B. T., Lizonová, A., Brough, D. E., Sowers, J., Sheets, R., Gall, J. G. D., Newton, P. A., & Gomez, P. (2006) · PubMed · Cited by 12
Self-citation
Cited by
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
DNA vaccines: ready for prime time?
Kutzler, M. A., & Weiner, D. B. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2432 · Cited by 1,077
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
McElrath, M. J., De Rosa, S. C., Moodie, Z., Dubey, S., Kierstead, L., Janes, H., Defawe, O. D., Carter, D. K., Hural, J., Akondy, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61592-5 · Cited by 713
Self-citationThe Challenge of HIV-1 Subtype Diversity
Taylor, B. S., Sobieszczyk, M. E., McCutchan, F. E., & Hammer, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706737 · Cited by 635
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Hammer, S. M., Sobieszczyk, M. E., Janes, H., Karuna, S. T., Mulligan, M. J., Grove, D., Koblin, B. A., Buchbinder, S. P., Keefer, M. C., Tomaras, G. D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310566 · Cited by 598
Self-citation
Metadata
- Authors
- Catanzaro, A. T., Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L., Martin, J. E., Novik, L., Chakrabarti, B. K., Butman, B. T., Gall, J. G. D., King, C. R., Andrews, C. A., Sheets, R., Gomez, P. L., Mascola, J. R., Nabel, G. J., Graham, B. S., & Vaccine Research Center 006 Study Team
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-12-15
- Volume
- 194
- Issue
- 12
- Pages
- 1638-1649
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2105809563
- Cited by
- 321
- References
- 37
- FWCI
- 12.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.